Aclaris Therapeutics (ACRS) Tops Q4 EPS by 4c

Aclaris Therapeutics (NASDAQ: ACRS) reported Q4 EPS of ($0.41), $0.04 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $7.8 million versus the consensus estimate of $1.99 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Ennis (EBF) Reports In-Line Q1 EPS
• Middleby board approves spin-off of food processing unit Midera